Skip to main content
NCBI home page
The Journal of Prevention of Alzheimer's Disease logoLink to The Journal of Prevention of Alzheimer's Disease
. 2026 Mar 14;13(4):100527. doi: 10.1016/j.tjpad.2026.100527

Corrigendum to “Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes” [The Journal of Prevention of Alzheimer's Disease (2026) 100507]

Richard Perry a, Christopher Kipps b, Maria Eugenia Soto Martín c, Marco Bozzali d,e, Giancarlo Logroscino f, Sarah Trafford g, Shobha Dhadda h, Michio Kanekiyo h, Amanda Goodwin g,h, Mark Hodgkinson g, Steven Hersch h, Michael Irizarry h, Lynn Kramer h, Lutz Froelich i,⁎
PMCID: PMC13000697  PMID: 41831370

We have replaced the previously published supplemental material with the Adobe pdf version rather than the Microsoft document version.

The new pdf version is identical to the previous document version, with the exception that we updated Figure S2B, including the figure legend to make the graph clearer for readers.

Articles from The Journal of Prevention of Alzheimer's Disease are provided here courtesy of Elsevier

RESOURCES